Cogent Biosciences, Inc.
COGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $69 | $61 | $63 | $62 |
| G&A Expenses | $14 | $13 | $12 | $12 |
| SG&A Expenses | $14 | $13 | $12 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $83 | $74 | $75 | $74 |
| Operating Income | -$83 | -$76 | -$75 | -$74 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $6 |
| Pre-Tax Income | -$81 | -$74 | -$72 | -$68 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$81 | -$74 | -$72 | -$68 |
| % Margin | – | – | – | – |
| EPS | -0.71 | -0.64 | -0.52 | -0.61 |
| % Growth | -10.9% | -23.1% | 14.8% | – |
| EPS Diluted | -0.71 | -0.64 | -0.52 | -0.61 |
| Weighted Avg Shares Out | 114 | 114 | 113 | 110 |
| Weighted Avg Shares Out Dil | 114 | 114 | 113 | 110 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $3 | $4 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$79 | -$72 | -$74 | -$73 |
| % Margin | – | – | – | – |